What is the drug of choice for listeria meningitis?
What is the best skin disinfectant for central line insertion?
What is the mechanism of action of quinolones?
As per RNTCP guidelines, Multi drug resistance (MDR) TB is defined as resistance to:
All are true about ciprofloxacin except?
Sulphonamide injection causes decrease in folic acid by?
Which antibiotic is primarily associated with Red man syndrome?
Which type of vaccine is used for chicken pox?
Which antibiotic is Actinomycosis sensitive to?
Which of the following drugs does not inhibit bacterial protein synthesis?
Explanation: ***Ampicillin*** - **Ampicillin** is the **drug of choice** for *Listeria monocytogenes* meningitis due to its excellent in vitro activity and good central nervous system penetration. - It is often used in combination with an **aminoglycoside** (e.g., gentamicin) for synergistic bactericidal activity, especially in severe cases, though gentamicin does not penetrate the CSF well. *Cefotaxime* - **Third-generation cephalosporins** like cefotaxime have poor activity against *Listeria monocytogenes* due to the organism's intrinsic resistance to these agents. - While effective against many other bacterial causes of meningitis (e.g., *S. pneumoniae*, *N. meningitidis*), it is not appropriate for *Listeria*. *Ceftriaxone* - Similar to cefotaxime, **ceftriaxone** is a third-generation cephalosporin and is **ineffective** against *Listeria monocytogenes* due to the lack of penicillin-binding protein (PBP) affinity. - Its use for *Listeria* meningitis would lead to treatment failure. *Ciprofloxacin* - **Ciprofloxacin**, a fluoroquinolone, is generally **not recommended** as a first-line treatment for *Listeria* meningitis, despite some in vitro activity. - Its use is typically reserved for patients with severe allergies to penicillins, and even then, **trimethoprim-sulfamethoxazole** is usually preferred as an alternative to ampicillin.
Explanation: ***Chlorhexidine*** - **Chlorhexidine (particularly >0.5% chlorhexidine in alcohol-based solution, such as 2% chlorhexidine in 70% isopropyl alcohol)** is the preferred antiseptic for central line insertion per **CDC guidelines**. - It provides **rapid onset of action**, persistent antimicrobial activity (lasting several hours), and broad-spectrum efficacy against gram-positive and gram-negative bacteria, fungi, and some viruses. - Superior to povidone-iodine in reducing catheter-related bloodstream infections (CRBSIs) in multiple studies. - Its mechanism involves disrupting bacterial cell membranes and coagulating intracellular contents, leading to sustained antimicrobial activity on the skin. *Povidone iodine* - **Povidone iodine** has a slower onset of action and is inactivated by organic matter (blood, serum), making it less effective for immediate, sustained disinfection compared to chlorhexidine. - While it has broad-spectrum activity, its residual effect is limited once it dries on the skin. - Studies show higher rates of catheter-related infections compared to chlorhexidine-based antiseptics. *Alcohol* - **Alcohol** (e.g., isopropyl alcohol or ethanol) provides good immediate microbial kill but lacks persistent activity, meaning its effect is short-lived as it evaporates quickly from the skin. - It works by denaturing proteins and dissolving lipids, but its rapid evaporation makes it insufficient as a sole agent for central line insertion. - Often used as a component in combination with chlorhexidine for optimal efficacy. *Cetrimide* - **Cetrimide** is a quaternary ammonium compound with antiseptic properties, but it has a narrower spectrum of activity and is less potent than chlorhexidine for surgical site preparation. - It is often used in combination with other agents or for general skin cleansing rather than for critical procedures like central line insertion. - Not recommended as a primary antiseptic for central venous catheter insertion.
Explanation: ***Inhibit DNA gyrase*** - Quinolones, particularly **fluoroquinolones**, exert their bactericidal effect by targeting **bacterial DNA gyrase (topoisomerase II)** and **topoisomerase IV**. - This inhibition prevents the uncoiling and replication of bacterial DNA, leading to cell death. *Bind to 30S ribosomal subunit* - This mechanism is characteristic of **aminoglycosides** and **tetracyclines**, which disrupt bacterial protein synthesis. - Quinolones do not interfere with ribosomal function but rather with **DNA replication**. *Bind to bacterial cell membrane* - This is the mechanism of action for **polymyxins** and **daptomycin**, which disrupt the integrity of the bacterial cell membrane. - Quinolones specifically target **intracellular enzymes** involved in DNA handling. *Inhibit tetrahydrofolate reductase* - This enzyme name in the option is technically imprecise; **trimethoprim** actually inhibits **dihydrofolate reductase**, which is part of the **sulfonamide-trimethoprim (Bactrim)** combination. - This pathway is involved in **folic acid synthesis**, crucial for bacterial DNA and RNA production, a mechanism distinct from quinolones.
Explanation: ***Rifampicin and isoniazid*** - According to **RNTCP guidelines** (now NTEP), **MDR-TB** is specifically defined as tuberculosis that is resistant to at least both **rifampicin** and **isoniazid**. - These two drugs are the **most potent first-line anti-TB medications**, and resistance to both significantly complicates treatment. *Rifampicin* - While resistance to **rifampicin alone** is a serious concern, it is classified as **rifampicin-resistant TB (RR-TB)**, not full **MDR-TB**. - **MDR-TB** requires resistance to at least two key first-line drugs. *Rifampicin, isoniazid and ethambutol* - Resistance to **rifampicin**, **isoniazid**, and **ethambutol** would be a form of **MDR-TB** (as it includes resistance to rifampicin and isoniazid), but it is a more extensive form of resistance. - The minimum definition of **MDR-TB** focuses on the two most crucial first-line drugs. *None of the above* - This option is incorrect because there is a specific definition for **MDR-TB** that aligns with one of the provided choices. - The guidelines clearly define **MDR-TB** based on resistance to specific drugs.
Explanation: ***More active at acidic pH*** - Fluoroquinolones, including ciprofloxacin, exhibit **reduced antibacterial activity in acidic environments**. Their efficacy is generally better at **neutral or alkaline pH**. - This is clinically relevant as fluoroquinolones may have **reduced effectiveness in acidic sites** like the stomach or acidic urine. - The optimal antibacterial activity occurs at physiological or slightly alkaline pH. *DNA gyrase inhibition* - Ciprofloxacin, like other fluoroquinolones, exerts its antibacterial effect by inhibiting **bacterial DNA gyrase (topoisomerase II)** and **topoisomerase IV**. - This inhibition prevents DNA replication and repair, leading to bacterial cell death. *Contraindicated in pregnancy* - Ciprofloxacin is generally **contraindicated in pregnancy** due to concerns about potential harm to the developing fetus, particularly effects on **cartilage development**. - However, it may be used in specific, life-threatening situations if the benefit outweighs the potential risk. *Second generation fluoroquinolone* - Ciprofloxacin is classified as a **second-generation fluoroquinolone**. - This class includes agents with improved activity against Gram-negative bacteria and some atypical organisms.
Explanation: ***Inhibition through competition with substrate***Sulphonamides are **structural analogs of p-aminobenzoic acid (PABA)**, a substrate crucial for dihydropteroate synthase [1, 2]. They competitively inhibit this enzyme, which synthesizes **dihydrofolic acid**, a precursor to **tetrahydrofolic acid (THF)**, thereby reducing folic acid production in bacteria [1, 2].*Inhibition without competition*This typically refers to **non-competitive inhibition**, where the inhibitor binds to an allosteric site and changes the enzyme's conformation, regardless of substrate concentration. Sulphonamides, however, specifically compete with PABA at the active site of **dihydropteroate synthase**.*Inhibition through a different site*This describes **allosteric inhibition** or non-competitive inhibition, where the inhibitor binds to a site other than the active site. Sulphonamides do not work through an allosteric mechanism; they directly interfere with the binding of PABA at the enzyme's active site.*Inhibition that does not involve the active site*This is another way to describe **non-competitive** or **allosteric inhibition**, where the inhibitor binds elsewhere on the enzyme, altering its function without directly blocking the active site. Sulphonamides' mechanism is distinct, as they closely resemble the natural substrate and directly compete for the active site of **dihydropteroate synthase**.
Explanation: **Vancomycin** - **Red man syndrome** is a well-known **infusion-related reaction** primarily associated with vancomycin. - It occurs due to the **rapid infusion** of vancomycin, leading to non-immunologic **mast cell degranulation** and histamine release. - Characterized by flushing, pruritus, and erythema of the upper body and face. - **Prevention:** Slow infusion rate (over 60 minutes or longer) and/or premedication with antihistamines. *Polymyxin B* - Polymyxin B is associated with **nephrotoxicity** and **neurotoxicity**, not typically with Red man syndrome. - It can cause **histamine release** leading to flushing and itching, but this is less common and less severe than with vancomycin. *Rifampicin* - Rifampicin is primarily known for causing **orange-red discoloration** of bodily fluids (e.g., urine, tears, sweat) and can cause **hepatotoxicity**, but not Red man syndrome. - It works by inhibiting bacterial **RNA synthesis** and is used to treat tuberculosis and other mycobacterial infections. *Teicoplanin* - Teicoplanin is a **glycopeptide antibiotic** similar to vancomycin, but it has a **significantly lower incidence** of Red man syndrome. - While it can cause some **infusion-related reactions**, they are generally milder and less frequent compared to vancomycin.
Explanation: ***Live vaccine*** - The chickenpox vaccine (Varicella vaccine) is a **live-attenuated vaccine**, meaning it contains a weakened form of the **Varicella-zoster virus** (Oka strain). - This weakened virus can still replicate in the body, stimulating a strong and long-lasting immune response similar to natural infection but without causing severe disease. *Killed vaccine* - **Killed (inactivated) vaccines** use viruses or bacteria that have been inactivated through heat or chemicals, making them unable to replicate. - While effective for some diseases (e.g., inactivated polio, influenza), they typically require **multiple doses** and might provide less durable immunity compared to live vaccines. *Conjugated vaccine* - **Conjugated vaccines** are designed to improve the immune response to polysaccharide antigens (e.g., bacterial capsules) by linking them to a carrier protein. - This technology is primarily used for **bacterial infections** like *Haemophilus influenzae* type b (Hib) or pneumococcal disease, not viral illnesses like chickenpox. *Toxoid vaccine* - **Toxoid vaccines** contain inactivated bacterial toxins (toxoids) rather than the whole organism. - Examples include **tetanus and diphtheria vaccines**, which protect against diseases caused by bacterial toxins, not viral infections like chickenpox.
Explanation: ***Penicillin*** - **Penicillin** is the **antibiotic of choice** for treating Actinomycosis due to the organism's high sensitivity. - Treatment typically involves a **long course** of high-dose penicillin for several months. *Streptomycin* - **Streptomycin** is an **aminoglycoside antibiotic** primarily used for **tuberculosis** and some gram-negative bacterial infections. - It is **not effective** against Actinomyces species. *Nystatin* - **Nystatin** is an **antifungal medication** used to treat **yeast infections**, particularly Candida. - It has **no antibacterial activity** and thus no role in treating Actinomycosis. *Doxycycline* - While **doxycycline** can be used as an **alternative** in patients allergic to penicillin, it is **not the primary choice**. - Its effectiveness is generally less pronounced than penicillin, and it's reserved for second-line treatment.
Explanation: ***Sulfonamides*** - Sulfonamides do **NOT** inhibit bacterial protein synthesis; instead, they inhibit **folic acid synthesis**. - They act as **competitive inhibitors** of dihydropteroate synthase, an enzyme involved in the synthesis of dihydrofolic acid. - Folic acid is essential for nucleotide synthesis and DNA replication, making sulfonamides bacteriostatic agents that work through a completely different mechanism than protein synthesis inhibitors. *Aminoglycosides* - Aminoglycosides bind to the **30S ribosomal subunit**, causing misreading of mRNA and premature termination of protein synthesis. - This leads to the production of **abnormal and non-functional proteins**, ultimately killing the bacterial cell. *Chloramphenicol* - Chloramphenicol binds to the **50S ribosomal subunit**, thereby inhibiting the peptidyl transferase enzyme. - This prevents the formation of **peptide bonds** between amino acids, effectively blocking protein elongation. *Clindamycin* - Clindamycin also binds to the **50S ribosomal subunit**, specifically at the P-site. - It interferes with the **translocation step** of protein synthesis, preventing ribosomal movement along the mRNA.
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free